China NT Pharma Group Balance Sheet Health
Financial Health criteria checks 2/6
China NT Pharma Group has a total shareholder equity of CN¥-346.4M and total debt of CN¥356.1M, which brings its debt-to-equity ratio to -102.8%. Its total assets and total liabilities are CN¥338.8M and CN¥685.2M respectively.
Key information
-102.8%
Debt to equity ratio
CN¥356.13m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥8.92m |
| Equity | -CN¥346.41m |
| Total liabilities | CN¥685.18m |
| Total assets | CN¥338.76m |
Recent financial health updates
Recent updates
A Look At The Intrinsic Value Of China NT Pharma Group Company Limited (HKG:1011)
Mar 06
China NT Pharma Group Company Limited's (HKG:1011) Price Is Right But Growth Is Lacking
Dec 29Estimating The Intrinsic Value Of China NT Pharma Group Company Limited (HKG:1011)
Oct 30Is China NT Pharma Group (HKG:1011) Using Too Much Debt?
Apr 13Financial Position Analysis
Short Term Liabilities: 1011 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: 1011 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: 1011 has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: 1011's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 1011 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 1011 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 49% per year.